Connecting Men, Families, Doctors, and other Medical Professionals to Clinical Trials for Prostate Cancer

        DISEASE CHARACTERISTICS:

          -  Histologically confirmed prostate cancer

          -  Must have had definitive surgery, radiotherapy, or cryoablation

          -  Must have hormone-sensitive prostate cancer by evidence of a serum total testosterone
             level > 150 ng/dL within the past 12 weeks

          -  Biochemical failure after primary therapy and subsequent progression determined by 1
             of the following:

               -  PSA >= 0.4 ng/mL for patients who had radical prostatectomy

               -  PSA rise >= 2 ng/mL above the nadir PSA for patients who had radiotherapy

          -  Patients must have 2 subsequent PSA rises (PSA2 and PSA3) obtained >= 2 weeks apart
             and each having a value higher than the previous one, with a PSA doubling time
             (PSADT) in < 12 months

               -  Baseline PSA >= 2 ng/mL and <= 50 ng/mL

          -  No metastatic disease by physical exam, CT scan or MRI of the abdomen and/or pelvis,
             chest x-ray (or CT chest), and bone scan within the past 8 weeks

        PATIENT CHARACTERISTICS:

          -  ECOG performance status 0-1

          -  Granulocytes >= 1,500/mm³

          -  Platelet count >= 100,000/mm³

          -  Serum creatinine normal OR creatinine clearance >= 60 mL/min

          -  Total bilirubin <= 1.5 times upper limit of normal (ULN)

          -  Alkaline phosphatase <= 2.5 times ULN

          -  AST and ALT < 2.5 times ULN

          -  Fertile patients must use effective barrier method of contraception during and for 3
             months after discontinuation of study treatment

          -  Not HIV positive

          -  No impaired cardiac function, including any of the following:

               -  Baseline QTcF > 450 msec (male)

               -  Congenital long QT syndrome

               -  History of sustained ventricular tachycardia

               -  Any history of ventricular fibrillation or torsades de pointes

               -  Bradycardia defined as heart rate < 50 beats per minute

                    -  Pacemaker and heart rate >= 50 beats per minute allowed

               -  Myocardial infarction or unstable angina within the past 6 months

               -  NYHA class III or IV congestive heart failure

               -  Right bundle branch block and left anterior hemi-block (bifascicular block)

          -  No gastrointestinal (GI) disease resulting in inability to take oral medications,
             malabsorption syndrome, a requirement for IV alimentation, prior surgical procedures
             affecting absorption, or uncontrolled inflammatory GI disease (e.g., Crohn disease or
             ulcerative colitis)

          -  No history of allergic reactions attributed to compounds of similar chemical or
             biologic composition to Akt inhibitor MK2206 or bicalutamide

          -  No uncontrolled intercurrent illness including, but not limited to, any of the
             following:

               -  Ongoing or active infection

               -  Cardiac arrhythmia

               -  Psychiatric illness and/or social situations that would limit compliance with
                  study requirements

          -  Patients with diabetes or at risk for hyperglycemia allowed provided it is controlled
             with oral agents

          -  More than 2 years since another malignancy that has been adequately treated and the
             patient has been disease-free

               -  No other currently active malignancy

        PRIOR CONCURRENT THERAPY:

          -  See Disease Characteristics

          -  Prior salvage therapy (surgery, radiotherapy, or other local ablative procedure) with
             curative intent within the past 4 weeks allowed

          -  Prophylactic radiotherapy to prevent gynecomastia within the past 4 weeks allowed

          -  Prior neoadjuvant and/or adjuvant therapy (chemotherapy, vaccines, or experimental
             agents) within the past 4 weeks allowed provided PSA rise and PSADT were documented
             after the testosterone level > 150 ng/dL

          -  At least 14 days since prior enzyme-inducing anti-epileptic drugs (EIAED)

               -  Non-EIAED allowed

          -  More than 2 weeks since prior and no concurrent cytochrome P450 EIAED (phenytoin,
             carbamazepine, or phenobarbital), St John wort, ketoconazole, dexamethasone,
             dysrhythmic drugs (terfenadine, quinidine, procainamide, sotalol, probucol, bepridil,
             indapamide, or flecainide), haloperidol, risperidone, rifampin, or grapefruit juice

          -  No prior therapy modulating testosterone levels (such as luteinizing hormone,
             releasing-hormone agonists/antagonists, or antiandrogens) within the past year

               -  Prior therapy modulating testosterone levels in the neoadjuvant and/or adjuvant
                  setting allowed

          -  No concurrent 5-alpha-reductase inhibitors, ketoconazole, abiraterone, MDV31000,
             megestrol acetate, systemic steroids, or herbal supplements

          -  No concurrent therapeutic administration of anticoagulant therapy

               -  Low-dosage aspirin <= 325 mg per day allowed

          -  No other concurrent investigational agents or anticancer therapy (e.g., chemotherapy,
             immunotherapy, radiation therapy, surgery for cancer, or experimental medications)

          -  No concurrent medications or substances that are inhibitors or inducers of CYP 450
             3A4

          -  No concurrent drugs with a risk of causing torsades de pointes